HIT Consultant July 24, 2025
What You Should Know:
– Trinity Biotech, a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, today unveiled its new flagship product, CGM+, a next-generation wearable biosensor platform designed for the $260 billion AI wearables market.
– Now in the later stages of device development, CGM+ is Trinity’s new AI-native continuous glucose monitoring (CGM) system, combining multi-sensor data and real-time analytics to meet the evolving demands of AI-powered healthcare and wellness.
Optimizing Continuous Glucose Monitoring
Unlike traditional CGMs that focus solely on glucose monitoring, CGM+ integrates an ultra-thin, minimally invasive electrochemical glucose sensor with continuous monitoring of heart activity, body temperature, and physical activity—all within a single, sleek, and user-friendly modular wearable device. This multimodal...
Today's Sponsors
Today's Sponsor